Analysts Set First Tracks Biotherapeutics (NASDAQ:TRAX) PT at $47.88

Shares of First Tracks Biotherapeutics (NASDAQ:TRAX – Get Free Report) have received a consensus rating of “Moderate Buy” from the nine analysts that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $50.3750.

A number of research firms have issued reports on TRAX. Barclays raised their price target on shares of First Tracks Biotherapeutics from $40.00 to $48.00 and gave the stock an “overweight” rating in a report on Tuesday, July 21st. Leerink Partners initiated coverage on shares of First Tracks Biotherapeutics in a report on Friday, April 24th. They set an “outperform” rating and a $46.00 price objective on the stock. Wall Street Zen raised First Tracks Biotherapeutics to a “hold” rating in a research report on Saturday, May 2nd. UBS Group raised their target price on First Tracks Biotherapeutics from $45.00 to $65.00 and gave the stock a “buy” rating in a research note on Monday. Finally, Zacks Research raised First Tracks Biotherapeutics to a “hold” rating in a research report on Monday, April 27th.

Get First Tracks Biotherapeutics alerts:

Get Our Latest Stock Analysis on TRAX

First Tracks Biotherapeutics Price Performance

Shares of TRAX stock opened at $46.13 on Thursday. First Tracks Biotherapeutics has a fifty-two week low of $14.72 and a fifty-two week high of $49.91. The stock has a market capitalization of $1.61 billion and a price-to-earnings ratio of -25.07. The business’s 50-day simple moving average is $29.33.

First Tracks Biotherapeutics (NASDAQ:TRAX – Get Free Report) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.74) by ($0.21). As a group, equities analysts expect that First Tracks Biotherapeutics will post -3.42 earnings per share for the current year.

About First Tracks Biotherapeutics

(Get Free Report)

First Tracks Biotherapeutics is a clinical stage biotechnology company advancing antibody therapies which modulate immune pathways implicated in autoimmune and inflammatory diseases. Its pipeline includes ANB033 and ANB101. First Tracks Biotherapeutics is based in SAN DIEGO.

Featured Stories

• Five stocks we like better than First Tracks Biotherapeutics
• GE Vernova’s AI Power Boom Faces a Profit Test
• Cardinal Health Earnings: Can Perfection Get Priced In Twice?
• Nebius’ Q2 Beat Shows the AI Bottleneck Is Capacity, Not Demand
• Legacy Jet Builders Stall While Embraer Accelerates to New Highs

Receive News & Ratings for First Tracks Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for First Tracks Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.